1. Home
  2. AMS vs EDSA Comparison

AMS vs EDSA Comparison

Compare AMS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

HOLD

Current Price

$2.21

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$1.03

Market Cap

12.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMS
EDSA
Founded
1980
2015
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.2M
12.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AMS
EDSA
Price
$2.21
$1.03
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.00
AVG Volume (30 Days)
9.4K
112.9K
Earning Date
11-13-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$29,423,000.00
N/A
Revenue This Year
$3.81
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.84
N/A
52 Week Low
$2.01
$0.94
52 Week High
$3.11
$4.49

Technical Indicators

Market Signals
Indicator
AMS
EDSA
Relative Strength Index (RSI) 63.85 27.97
Support Level $2.09 $0.94
Resistance Level $2.15 $1.11
Average True Range (ATR) 0.07 0.14
MACD 0.02 -0.01
Stochastic Oscillator 61.28 15.69

Price Performance

Historical Comparison
AMS
EDSA

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: